There are currently 942 clinical trials in Durham, North Carolina looking for participants to engage in research studies. Trials are conducted at various facilities, including Duke University Medical Center, Duke University, Duke Comprehensive Cancer Center and Duke University health system. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902
Recruiting
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Durham VA Medical Center, Durham, North Carolina +1 locations
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Register for Updates
Tocilizumab in Lung Transplantation
NCT06033196
Recruiting
This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (six doses over 20 weeks) plus standard triple maintenance immunosuppression or placebo (sterile normal saline) plus standard triple maintenance immunosuppression (Tacrolimus, Mycophenolate Mofetil, corticosteroids). The primary objective is to test the hypothesis that treatment with triple maintenance immunosuppression plus Tocilizumab (TCZ) is superior to triple maintenance i... Read More
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
06/20/2024
Locations: Duke University Medical Center (Site #: 71139), Durham, North Carolina
Conditions: Lung Transplant
Register for Updates
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
NCT06196008
Recruiting
This clinical trial compares telephone-based physical activity coaching to self monitored physical activity for improving physical function in older adults who are undergoing surgery for lung cancer and their caregivers. Lung cancer surgery in older adults is associated with functional declines and unique challenges. Performing physical activity around the time of surgery has been shown to improve functional outcomes in patients and exercise programs delivered via telehealth may improve access a... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Duke University, Durham, North Carolina
Conditions: Lung Carcinoma
Register for Updates
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
NCT04166409
Recruiting
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs... Read More
Gender:
All
Ages:
Between 2 years and 21 years
Trial Updated:
06/20/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Low Grade Glioma, Low Grade Astrocytoma, Metastatic Low Grade Astrocytoma, Metastatic Low Grade Glioma
Register for Updates
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
NCT06036836
Recruiting
The purpose of this study is to evaluate pathological complete response (pCR) rate of coformulated favezelimab/pembrolizumab (MK-4280A) or pembrolizumab as assessed by blinded central pathology review (BICR) in participants with cutaneous squamous cell carcinoma (cSCC) [Cohort A] and to evaluate lenvatinib in combination with coformulated favezelimab/pembrolizumab or pembrolizumab with respect to objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as asses... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Duke Cancer Institute ( Site 0641), Durham, North Carolina
Conditions: Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer
Register for Updates
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
NCT05166889
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior... Read More
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
06/20/2024
Locations: Research Site, Durham, North Carolina
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Register for Updates
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
NCT03615235
Recruiting
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from ki... Read More
Gender:
All
Ages:
0 years and above
Trial Updated:
06/20/2024
Locations: Duke University, Durham, North Carolina
Conditions: Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
Register for Updates
A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
NCT05384626
Recruiting
Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of NVL-655, determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ALK- positive (ALK+) NSCLC and other solid tumors. Phase 1 will evaluate the overall safety and tolerability of NVL-655 and will determine the RP2D and, if applicable, the MTD of NVL-655 in patients with advanced ALK+ solid tumors. Phase 2 will determine the objective response rat... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
06/20/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075
Recruiting
This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates
A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
NCT05831176
Recruiting
The study is researching an experimental drug called dupilumab. The study is focused on participants with active eosinophilic gastritis (EoG) with or without eosinophilic duodenitis (EoD). Participants with EoD only are not eligible for enrollment. EoG and EoD are uncommon, persistent, allergic/immune diseases in which eosinophils (a type of white blood cell) gather in large numbers in the stomach and small intestine and cause inflammation and damage. The aim of the study is to evaluate the eff... Read More
Gender:
All
Ages:
12 years and above
Trial Updated:
06/20/2024
Locations: Duke University Health System, Durham, North Carolina
Conditions: Eosinophilic Gastritis, Eosinophilic Duodenitis, Eosinophilic Gastrointestinal Disease
Register for Updates
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
NCT04706923
Recruiting
The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV
Gender:
All
Ages:
2 months and above
Trial Updated:
06/20/2024
Locations: Research Site, Durham, North Carolina
Conditions: Adenovirus Infections, Cytomegalovirus Infection
Register for Updates
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049
Recruiting
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolism
Register for Updates